L’impatto della cross-copertura di dupilumab sulla spesa a carico del Servizio Sanitario Nazionale

BACKGROUND AND RESEARCH QUESTION: Label extension for treatments and the relevant disease cross-coverage may produce an economic benefit. This paper assesses this benefit for dupilumab in the perspective of the Italian National Health Service. Dupilumab was approved for reimbursement for severe atop...

Descripción completa

Detalles Bibliográficos
Autores principales: Jommi, Claudio, Cipriani, Filippo, Fanelli, Francesca, Pedone, Maria P., Canonica, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677606/
https://www.ncbi.nlm.nih.gov/pubmed/36627967
http://dx.doi.org/10.33393/grhta.2020.2139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677606/
https://www.ncbi.nlm.nih.gov/pubmed/36627967
http://dx.doi.org/10.33393/grhta.2020.2139

Ejemplares similares